Alzheimer's Research & Therapy

Table 3 AD-PRSs versus log plasma p-tau181 in Aβ-positive and Aβ-negative individuals

From: Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative

	*APOE* PRS				Non-*APOE* PRS
	Aβ pos (n = 322)
PRS version	β	SE	95% CI	p	β	SE	95% CI	p
34-SNP PRS	0.10	0.03	0.05–0.15	7e−5	0.06	0.02	0.01–0.10	0.02
5e−8 PRS	0.10	0.03	0.05–0.15	9e−5	0.05	0.02	0.01–0.10	0.02
1e−5 PRS	0.10	0.03	0.05–0.15	2e−4	0.05	0.02	− 0.001 to 0.09	0.06
PHS*	0.10	0.03	0.05–0.22	2e−4	0.09	0.04	0.01–0.17	0.02
	Aβ neg (n = 409)
	β	SE	95% CI	p	β	SE	95% CI	p
34-SNP PRS	0.15	0.04	0.07–0.23	2e−4	0.01	0.03	− 0.05 to 0.08	0.7
5e−8 PRS	0.17	0.04	0.09–0.25	5e−5	0.04	0.04	− 0.04 to 0.10	0.3
1e−5 PRS	0.14	0.04	0.06–0.22	1e−3	−0.003	0.03	− 0.07 to 0.06	0.9
PHS*	0.14	0.04	0.06–0.15	1e−3	0.08	0.08	− 0.07 to 0.24	0.3

Results are adjusted for sex, age, principal components, and diagnostic status. Significant p values are shown in bold
*Values presented in the “non-APOE PRS column” are adjusted for ε4-carriership instead of excluding APOE

Back to article page

ISSN: 1758-9193

Contact us

General enquiries: journalsubmissions@springernature.com